A noninvasive squamous cell carcinoma test can help differentiate high- and low-risk tumors and individualize management.” — Heather Gates, PA-C, DFAAPA WILDWOOD, FL, UNITED STATES, November 14, 2025 / EINPresswire.com / -- Squamous cell carcinoma (SCC) is one of the most common types of skin cancer. While many cases are treatable, some forms can grow quickly and become life-threatening. Right now, doctors determine how serious an SCC is by looking at what they can see in the clinic or under a m

Consumers often assume that if something is a supplement, it must be safe. But as we are seeing with kratom, unregulated products can have serious and lasting effects on the skin and the the body.” — Sonia P. Goyal, MD DALLAS, TX, UNITED STATES, November 14, 2025 / EINPresswire.com / -- Kratom is a plant-based supplement that people in the United States can easily buy online or in stores. Some people use it to get more energy, feel less pain, or help with drug withdrawal. But new research shows

Phase 1 trial evaluating GTB-3650 TriKE® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026 GTB-5550 TriKE® IND submission for B7H3-expressing solid tumors expected in late December 2025 or January 2026 SAN FRANCISCO, CALIFORNIA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutic

National health advocacy organizations call on Congressional leadership to honor commitment to vote on critical healthcare subsidies in December WASHINGTON, DC, UNITED STATES, November 14, 2025 / EINPresswire.com / -- Today, NMAC, formerly known as the National Minority AIDS Council, alongside 17 of its Coalition for Justice and Equity Across Movements partners (see full list below), responded to Congress passing a continuing resolution to reopen the government through January 30, 2026, while ca

Windtree has a total of 59 issued or allowed patents and 17 pending patents for Istaroxime and its SERCA2a activators Windtree received recent notification of allowed Istaroxime patents for acute heart failure in Canada and Mexico The pure SERCA2a activators patent for acute heart failure was granted in Isreal WARRINGTON, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversified company with several divisions and focused on

Pfizer's first wave of PD-1xVEGF trials, Akeso's first overall survival win from ivonescimab and more deals from Eli Lilly made our news this week. Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for its first-in-class ivonescimab. Eli Lilly signed two more drug discovery pacts, continuing a dealmaking spree. And more.1. With Summit leading the pack in PD-1xVEGF bispecifics, Pfizer lays out its own plan to rep

MELBOURNE, Australia, Nov. 14, 2025 /PRNewswire/ -- Samson Clinical ( Samson), an Australian pharmaceutical company focused on developing innovative treatments for hair loss, today announced the successful completion of recruitment in its SAM-002 Phase 3 clinical trial for androgenetic alopecia ( AGA) in men (male pattern hair loss). "The rapid enrolment in consistent with the strong unmet need among men for safe and highly effective hair loss treatments that have no undesirable impact on libido

With recent progress in 3D liver spheroid models, "miniature livers" can now thrive inside the lab—an area where Creative Biolabs has been actively involved. SHIRLEY, NY, UNITED STATES, November 14, 2025 / EINPresswire.com / -- For more than a decade, liver disease research and drug toxicity testing have been constrained by a persistent limitation—traditional 2D cell cultures are simply too "flat." Cells grown on a dish cannot mimic the intricate structure and dynamic interactions of real tissue

GLEN ALLEN, Va., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2025. Cary Claiborne, CEO of Adial Pharmaceuticals, commented, “We continue to achieve meaningful milestones on our path toward U.S. Food

Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl) Dotinurad, a next-generation URAT1 inhibitor, is advancing in two Phase 3 clinical trials with potenti